Discover 1,943 paid clinical trials in Fort Worth, Texas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Fort Worth offers a range of medical research opportunities, focusing on conditions such as cancer, cardiovascular disease, PTSD, and COVID-19. Healthy volunteers looking for paid opportunities, as well as those with specific health concerns, can participate in studies at the city’s leading healthcare facilities, gaining access to new and innovative treatments while contributing to advancements in medical research.
Filter
2
Filter results
Results: 1,943
A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications
for
Movement Disorders, Neurology, Parkinsons Disease
Location: Dallas TX, Baltimore MD, Philadelphia PA, New York NY
Sponsor: InSightec
Sex: All
Age: 30 - 70+
Code: NCT05539196
Recruiting
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
for
Breast Cancer
Location: Dallas TX, Tyler TX, Austin TX, San Antonio TX,
Sponsor: Greenwich LifeSciences, Inc.
Sex: All
Age: 18 - 70+
Code: NCT05232916
Phase 3, Recruiting
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
for
AL Amyloidosis, Amyloidosis
Location: Dallas TX, Nashville TN
Sponsor: University of Texas Southwestern Medical Center
Sex: All
Age: 18+
Code: NCT05145816
Phase 1, Phase 2, Recruiting
O. Formigenes Colonization in Calcium Oxalate Kidney Stone Disease
for
Kidney Stone, Kidney Calculi, Urolithiasis,
Location: Dallas TX, Birmingham AL
Sponsor: University of Alabama at Birmingham
Sex: All
Age: 18 - 70+
Code: NCT06330246
Recruiting
Training for Urinary Leakage Improvement After Pregnancy
for
Urinary Incontinence, Delivery Complication
Location: Dallas TX, Chicago IL, Durham NC, San Diego CA,
Sponsor: NICHD Pelvic Floor Disorders Network
Sex: Female
Age: 18+
Code: NCT06411158
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass
for
Acquired Antithrombin Deficiency
Location: Dallas TX, Oklahoma City OK, Columbus OH,
Sponsor: Octapharma
Sex: All
Age: 18 - 70+
Code: NCT06096116
Phase 3, Recruiting
Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study
for
Chronic Subdural Hematoma
Location: Dallas TX, San Antonio TX, Houston TX, Galveston TX,
Sponsor: The University of Texas Medical Branch, Galveston
Sex: All
Age: 40 - 70+
Code: NCT06347796
Recruiting
Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
for
Severe Hemophilia A
Location: Dallas TX
Sponsor: Octapharma
Sex: Male
Age: 12+
Code: NCT05935358
Phase 4, Recruiting
MEASuRE: Metreleptin Effectiveness And Safety Registry
for
Generalised Lipodystrophy, Partial Lipodystrophy
Location: Dallas TX, Kansas City KS, Chicago IL, Columbus OH,
Sponsor: Chiesi Farmaceutici S.p.A.
Sex: All
Age: 0+
Code: NCT02325674
Recruiting
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
for
Colorectal Neoplasms
Location: Dallas TX, Temple TX, Abilene TX, Round Rock TX,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT06662786
Phase 3, Recruiting
Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus
for
Cutaneous Lupus Erythematosus (CLE)
Location: Dallas TX, Philadelphia PA
Sponsor: University of Pennsylvania
Sex: All
Age: 18+
Code: NCT01510067
Recruiting
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors